Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000142730
Ethics application status
Approved
Date submitted
5/02/2013
Date registered
6/02/2013
Date last updated
18/07/2018
Type of registration
Prospectively registered
Titles & IDs
Public title
Does Arginine supplementation need to be part of routine clinical education for Diabetes Educators in the management of foot ulcers
Query!
Scientific title
L-Arginine supplemented diet in Type 2 Diabetes (T2DM) adult clients attending community health services in Townsville: does it improve healing in diabetic foot ulcers?
Query!
Secondary ID [1]
281849
0
Nil Known
Query!
Universal Trial Number (UTN)
Nil Known
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes
288210
0
Query!
Diabetic Foot Ulcers
288211
0
Query!
Condition category
Condition code
Diet and Nutrition
288577
288577
0
0
Query!
Other diet and nutrition disorders
Query!
Metabolic and Endocrine
288655
288655
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Arm 1 (intervention group) will be provided with 4.5 gms of L-Arginine powder per day for 12 weeks orally. The powder can be mixed with water
Query!
Intervention code [1]
286408
0
Treatment: Other
Query!
Comparator / control treatment
Arm 2 (Comparator group) will be given placebo 4.5 gms per day for 12 weeks orally. The placebo will be identical in appearance to L-Arginine without the active ingredient
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
288794
0
Foot ulcer healing rate measurement using UTWCS (University of Texas Wound Classification System) tool
Query!
Assessment method [1]
288794
0
Query!
Timepoint [1]
288794
0
At the start (week 1), every occasion of podiatric care and at 12 weeks as part of the study and the clients existing treatment
Query!
Secondary outcome [1]
301003
0
Foot Health status questionnaire
Query!
Assessment method [1]
301003
0
Query!
Timepoint [1]
301003
0
At the start (week 1) and 12 weeks
Query!
Secondary outcome [2]
301004
0
SF-26 questionnaire for QOL (Quality of Life)
Query!
Assessment method [2]
301004
0
Query!
Timepoint [2]
301004
0
To be assessed at week 1 and week 12
Query!
Secondary outcome [3]
301005
0
Nutrition status using food frequency questionnaire
Query!
Assessment method [3]
301005
0
Query!
Timepoint [3]
301005
0
Week 1, 6 and 12
Query!
Secondary outcome [4]
301006
0
Blood glucose monitoring for diabetes management
Query!
Assessment method [4]
301006
0
Query!
Timepoint [4]
301006
0
Week 1, and every second week for blood glucose and
Week 1 and 12 for HbA1c
Query!
Eligibility
Key inclusion criteria
Free living clients over the age of 18 yrs, attending the Townsville Community Health Services
Clients with Type 2 Diabetes
Clients with diabetic foot ulcers
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Clients under the age of 18 Pregnant women Clients with food allergies and intolerances Clients who are on Renal Dialysis Clients who have had a fracture, within 3 months of the start of the trial Clients who have been diagnosed with cirrhosis of the liver had burns to 10% or more of his/her body, within 6 months of the start of the trial. Clients who have suffered a heart attack, within 3 months of the start of the trial. Clients who have been scheduled for surgery within two weeks of the start of the trial or during the trial Clients who have low blood pressure. Women who are pregnant and/or breast feeding
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All clients who fit the selection criteria will be invited to participate, and if willing will be provided information on the study and participant consent will be obtained and then enrolled for the study.
Once enrolled in the study they will be randomly allocated to one of the 2 groups, based on a random number table by a clinical nurse/admin who is not involved in the study.
As it is a double blind placebo controlled RCT both clinicians and participants will not be aware of the allocation or the group into which they have been grouped
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Based on a random number table in numerical order of enrollment
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
SPSS software will be used
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
3/12/2018
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
28/02/2020
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
160
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment postcode(s) [1]
6246
0
4817 - Kirwan
Query!
Funding & Sponsors
Funding source category [1]
286681
0
Charities/Societies/Foundations
Query!
Name [1]
286681
0
Australian Diabetes Educators Association
Query!
Address [1]
286681
0
Post: PO Box 163
Woden ACT 2606
Query!
Country [1]
286681
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
Australian Diabetes Educators Association
Query!
Address
Post: PO Box 163
Woden ACT 2606
Query!
Country
Australia
Query!
Secondary sponsor category [1]
285455
0
Hospital
Query!
Name [1]
285455
0
Queensland Health
Query!
Address [1]
285455
0
Townsville Hospital and Health Services
Townsville Community Health Services
138, Thuringowa Drive
Kirwan
QLD 4817
Query!
Country [1]
285455
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
288749
0
Townsville Hospital Human Research and Ethics Committee
Query!
Ethics committee address [1]
288749
0
100, Angus Smith Drive Douglas Townsville QLD 4814
Query!
Ethics committee country [1]
288749
0
Australia
Query!
Date submitted for ethics approval [1]
288749
0
18/02/2013
Query!
Approval date [1]
288749
0
04/03/2013
Query!
Ethics approval number [1]
288749
0
Query!
Summary
Brief summary
Diabetes is a multi-factorial disease, with a multi-disciplinary approach being advocated for diabetes treatment and the prevention of its complications. In Australia, diabetes is the most common cause of lower limb amputation after trauma. Diabetic foot ulcers are responsible for a substantial medical and financial burden on the Australian healthcare system with costs conservatively estimated to be as high as $45,000 per patient. Improved nutritional status and nutrition supplementation accelerate wound healing while inadequate nutrition prolongs wound healing. During wound healing non-essential amino acids, such as L-Arginine, becomes essential as it enhances a number of pathways involved in wound healing, protein metabolism, such as structural protein synthesis and collagen. Aim: To determine whether supplementation with L-Arginine will improve the healing of diabetic foot ulcers in a routine community based client education and management program conducted by medical and allied health professionals. Methods: This study is being designed as a double blinded RCT (treatment group: n=37+7, 4.5g L-arginine; control group n=19+7 placebo) for 12 weeks. Power calculations indicate 70 patients are required to provide adequate statistical power including anticipated attrition rate. The study will be conducted in a routine community based client education and management setting which includes health professionals (medical, podiatry, dietetic, diabetes educators) as part of a multi-disciplinary approach and holistic care for the client
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
37378
0
Mrs Achamma Joseph
Query!
Address
37378
0
Senior Dietitian Diabetes and Indigenous Health
Townsville Community Health Services
138, Thuringowa Drive
Kirwan
Townsville
QLD 4817
Query!
Country
37378
0
Australia
Query!
Phone
37378
0
0061437330442
Query!
Fax
37378
0
Query!
Email
37378
0
[email protected]
Query!
Contact person for public queries
Name
37379
0
Achamma Joseph
Query!
Address
37379
0
Senior Dietitian Diabetes and Indigenous Health
Townsville Community Health Services
138, Thuringowa Drive
Kirwan
Townsville
QLD 4817
Query!
Country
37379
0
Australia
Query!
Phone
37379
0
0061437330442
Query!
Fax
37379
0
Query!
Email
37379
0
[email protected]
Query!
Contact person for scientific queries
Name
37380
0
Achamma Joseph
Query!
Address
37380
0
Senior Dietitian Diabetes and Indigenous Health
Townsville Community Health Services
138, Thuringowa Drive
Kirwan
Townsville
QLD 4817
Query!
Country
37380
0
Australia
Query!
Phone
37380
0
0061437330442
Query!
Fax
37380
0
Query!
Email
37380
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF